IBDEI1BG ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22376,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,22376,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,22377,0)
 ;;=C91.40^^87^981^79
 ;;^UTILITY(U,$J,358.3,22377,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22377,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,22377,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,22377,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,22378,0)
 ;;=C91.42^^87^981^77
 ;;^UTILITY(U,$J,358.3,22378,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22378,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,22378,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,22378,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,22379,0)
 ;;=C91.41^^87^981^78
 ;;^UTILITY(U,$J,358.3,22379,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22379,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,22379,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,22379,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,22380,0)
 ;;=D57.01^^87^981^80
 ;;^UTILITY(U,$J,358.3,22380,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22380,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,22380,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,22380,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,22381,0)
 ;;=D57.00^^87^981^81
 ;;^UTILITY(U,$J,358.3,22381,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22381,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,22381,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,22381,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,22382,0)
 ;;=D57.02^^87^981^82
 ;;^UTILITY(U,$J,358.3,22382,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22382,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,22382,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,22382,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,22383,0)
 ;;=D68.32^^87^981^84
 ;;^UTILITY(U,$J,358.3,22383,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22383,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,22383,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,22383,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,22384,0)
 ;;=C22.2^^87^981^85
 ;;^UTILITY(U,$J,358.3,22384,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22384,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,22384,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,22384,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,22385,0)
 ;;=D58.9^^87^981^87
 ;;^UTILITY(U,$J,358.3,22385,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22385,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,22385,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,22385,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,22386,0)
 ;;=C81.99^^87^981^88
 ;;^UTILITY(U,$J,358.3,22386,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22386,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,22386,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,22386,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,22387,0)
 ;;=C81.90^^87^981^89
 ;;^UTILITY(U,$J,358.3,22387,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22387,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,22387,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,22387,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,22388,0)
 ;;=D89.2^^87^981^90
 ;;^UTILITY(U,$J,358.3,22388,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22388,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,22388,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,22388,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,22389,0)
 ;;=D05.12^^87^981^91
 ;;^UTILITY(U,$J,358.3,22389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22389,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
